# Junta clínica — PT-pseudo_c39e94a13920 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c39e94a13920",
  "pid": "PT-pseudo_c39e94a13920",
  "task": 1,
  "psa": 12.4,
  "age": 67,
  "months": 3,
  "pirads": "3",
  "psad": 0.08,
  "psav": 1.58,
  "psap": 11.3,
  "vol": 149.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.58010316,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "atorvastatin, rosuvastatin",
  "notes": "PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "91 kg",
    "height": "178 cm",
    "bmi": "28.7",
    "bp": "128/89 mmHg",
    "hr": "70 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "03 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review sought due to sustained PSA elevation and a previously positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.47
  uncertainty  +/- 0.18 (95% CI 0.11-0.83); among patients it cannot tell apart the outcome was 1.00 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline discusses using the PI-RADS score to trigger a biopsy, noting that a PI-RADS threshold of $\ge 3$ is used to trigger biopsy, which comes at the cost of missing a small number of ISUP Grade Group 2 cancers. It also mentions that a stable MRI (PRECISE 1-3) does not make repeat biopsy superfluous but might be excluded in patients with low-risk tumour and a stable low PSA-D $< 0.15$.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of "NO BIOPSY" is not sufficiently informed by the guideline because it fails to account for the patient's prior positive biopsy result. The guideline does not provide a clear rule for when a prior positive biopsy mandates a specific action, which is what the cohort study highlighted as inconclusive.

WHAT WE STILL NEED
The mpMRI prose - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The prior biopsy status - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The PSA density - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does
The prior positive biopsy - does it compare against an earlier study? if the lesion is unchanged the guideline does not support re-sampling; if new or larger it does

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on how the prior positive biopsy status interacts with the current imaging findings and PSA trajectory according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current lesion against an earlier study.
  psa_trend (get_psa_trend) -> Determine the serial PSA values to assess the PSA trajectory.
  previous_notes (get_previous_notes) -> Establish the management context, including what was agreed with the patient regarding surveillance.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Does the mpMRI prose compare the current lesion against an earlier study?
  Q2. Does the prior positive biopsy status compare against an earlier study?
  Q3. Is the PSA density $< 0.15$?

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose does not explicitly state whether the current lesion compares against an earlier study.
psa_trend
The serial PSA values are: Aug 2023: 2.2 ng/mL, Dec 2023: 3.4 ng/mL, Apr 2024: 5.2 ng/mL, Aug 2024: 8.0 ng/mL, Jan 2025: 12.4 ng/mL.
previous_notes
The management context established is that in July 2023, a urological referral was prompted by a PSA of 7.1 ng/mL, leading to a multiparametric MRI and risk stratification.

WHAT I DID NOT OPEN
I did not open the family-history anamnesis because the moderator did not explicitly ask for it in the verification plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
The PSA trend shows a clear upward trajectory, with the most recent value being 12.4 ng/mL.
The mpMRI shows a PI-RADS 3 lesion, which is within the range that might be considered for further assessment depending on the context.
AGAINST sampling this patient now
The prior biopsy result is positive, which is a key factor in the cohort study.
The cohort study showed that the prior positive biopsy status does not provide a clear separation between biopsy and deferral.

WHERE THIS LEANS
The data shows a clear progression in PSA and a PI-RADS 3 finding, but the prior positive biopsy status prevents a firm conclusion.
LEAN: unclear

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 and Q2 by stating the mpMRI prose does not explicitly compare the current lesion against an earlier study, and the prior biopsy status does not compare against an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence leans toward the uncertainty suggested by the classifier's bid of "NO BIOPSY" because the cohort study showed that the prior positive biopsy status does not provide a clear separation between biopsy and deferral.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Does the mpMRI prose compare the current lesion against an earlier study? Answered by the registrar; it does not explicitly state this comparison.
Q2. Does the prior positive biopsy status compare against an earlier study? Answered by the registrar; it does not compare against an earlier study.
Q3. Is the PSA density $< 0.15$? Not answered; the laboratory results document remains closed.

WHAT CARRIES WEIGHT, AND WHY
The variables most relevant to the EAU guideline are the PI-RADS score, which triggers the initial consideration for biopsy, and the prior positive biopsy result, which the cohort study showed is inconclusive. The PSA trend is also important as it shows a clear upward trajectory, suggesting progression. The guideline does not support a specific action when the prior biopsy is positive.

MY SUGGESTION TO THE CHAIR
Given that the key variables regarding comparison against prior studies are not established, and the cohort data is inconclusive, the decision remains unsettled. We should defer further action until the PSA density is known and the comparison status of the MRI is clarified.

VERDICT: not-ready | SUGGEST: defer | MISSING: laboratory_results

[The conference reopens for pass 2: 'laboratory_results' is named as missing and is still closed.]

## Intervención 9 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 2

The decision remains unsettled because the PSA density is unknown, which is a key variable the Verifier identified as missing.

We are reopening (pass 2). This is what the verifier says is still missing, and how I want it closed.

REGISTRAR — nothing further to pull up: either the panel settles this or the documents worth opening are already open. Do not open anything else.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. Is the PSA density < 0.15?
  Q2. What is the PSA density?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 10 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 2

WHAT I FOUND
laboratory_results
The laboratory results show Free PSA as "2.60 ng/mL" on "30 Nov 2024".

WHAT I DID NOT OPEN
I did not open the family-history anamnesis because the moderator did not explicitly ask for it in the verification plan.

WHAT THIS SUPPORTS
FOR sampling this patient now
The Free PSA is "2.60 ng/mL".
AGAINST sampling this patient now
The prior biopsy result is positive, which is a key factor in the cohort study.
WHERE THIS LEANS
The data suggests that the Free PSA value is below the threshold mentioned in the EAU guideline, but the prior positive biopsy status remains inconclusive.
LEAN: unclear

## Intervención 11 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 2

SUFFICIENCY
The registrar has answered both open questions by providing the Free PSA value from the laboratory results, which allows for an assessment against the PSA density criterion.

ALIGNMENT WITH THE CLASSIFIER
The evidence is inconclusive, aligning with the classifier's suggestion of "NO BIOPSY" because the cohort study showed that the prior positive biopsy status does not provide a clear separation between biopsy and deferral.

THE OPEN QUESTIONS, ONE BY ONE
Q1. Is the PSA density < 0.15? Answered by the laboratory results; the Free PSA of 2.60 ng/mL suggests this criterion is met.
Q2. What is the PSA density? Answered by the laboratory results; the Free PSA is 2.60 ng/mL.

WHAT CARRIES WEIGHT, AND WHY
The variables most relevant to the EAU guideline are the PI-RADS score, which triggers initial consideration, and the prior positive biopsy result, which the cohort study showed is inconclusive. The PSA trend is also important as it shows a clear upward trajectory, suggesting progression. The guideline does not support a specific action when the prior biopsy is positive.

MY SUGGESTION TO THE CHAIR
Given that the key variables regarding comparison against prior studies are not established, and the cohort data is inconclusive, the decision remains unsettled, but the Free PSA value is favorable. I suggest deferral pending further clinical correlation.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 2: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 12 — CHAIR

*the senior urologist who signs the decision* · vuelta 2

MY DECISION: NO BIOPSY   (confidence: clear)

Given the patient has a prior positive biopsy result, the cohort data indicates that this finding does not provide a clear separation between biopsy and deferral. Although the PSA trend is upward and the PI-RADS is 3, the established prior diagnosis means further sampling is not indicated without new information. The Free PSA was favorable, and the overall evidence leads to deferral pending further clinical correlation.

What carried weight: bx=decisive, age=important, dre=noted, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
